EBI-005 fails to meet co-primary endpoints in phase 3 study for dry eye disease

EBI-005 failed to meet its co-primary endpoints in a pivotal phase 3 study in patients with moderate to severe dry eye disease, according to top-line results from the OASIS study released by Eleven Biotherapeutics. The co-primary endpoints were to compare total corneal fluorescein staining score and patient-reported measurement related to ocular pain and discomfort based on the Ocular Surface Disease Index from baseline to week 12 for treatment with EBI-005 and treatment with vehicle control.